CTRI/2011/05/001754已完成2 期
Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy And Safety Study Of Tanezumab As Add-On Therapy To Opioid Medication In Patients With Pain Due To Bone Metastases - NONE
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Prostate cancer, breast cancer, renal cell carcinoma or multiple myeloma that has spread to bone, causing moderate to severe bone pain.
- •2.Requires daily opioid medication
- •Note: there is no upper age limit for inclusion criteria for this trial
排除标准
- •1.Patients who do not have bone pain caused by cancer are not eligible for the study.
- •2.Patients who started chemotherapy less than 4 weeks ago, or who completed radiotherapy less than 4 weeks ago, are not eligible.
- •3.Known history or evidence of osteoarthritis. History of significant trauma to a major joint within 1 year prior to Screening.
- •4.Known history of rheumatoid arthritis.
研究者
相似试验
已完成
不适用
A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To BoneC795-C795 Secondary malignant neoplasm of bone and bone marrowSecondary malignant neoplasm of bone and bone marrowPER-020-09PFIZER S.A.,
招募中
1 期
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code: 10072757Term: Chronic spontaneous urticaria Class: 100000004858CTIS2022-503062-72-00Incyte Corp.136
已完成
不适用
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Lecithinized Superoxide Dismutase Nebulizer (PC-SOD NE) in Adult Patients with Moderate Idiopathic Pulmonary Fibrosisidiopathic pulmonary fibrosisJPRN-UMIN000009572TT Bio-Pharma Co., Ltd.96
已完成
不适用
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-0303) in Patients with dry eye syndromedry eye syndromeJPRN-UMIN000021601TT Bio-Pharma Co., Ltd.20
招募中
1 期
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase DeficiencyMedDRA version: 21.1Level: LLTClassification code 10013373Term: Disorders of urea cycle metabolismSystem Organ Class: 100000004850Ornithine transcarbamylase deficiencyEUCTR2021-001081-38-ITArcturus Therapeutics, Inc.24